Literature DB >> 14512310

IL-13 production by donor T cells is prognostic of acute graft-versus-host disease following unrelated donor stem cell transplantation.

William J Jordan1, Paul A Brookes, Richard M Szydlo, John M Goldman, Robert I Lechler, Mary A Ritter.   

Abstract

Despite the success of human leukocyte antigen (HLA) typing in allogeneic stem cell transplantation (SCT) it is rare to find an unrelated donor that is perfectly matched, making identification of "permissive" mismatches of paramount importance. Here, we describe novel associations between donor T-cell cytokine production during donor-antipatient mixed lymphocyte reactions (MLRs) and acute graft-versus-host disease (aGVHD). The data reveal positive correlations between both Th1-type and Th2-type cytokine production and GVHD and the assay established could potentially represent a useful tool for identification of permissible unrelated SCT donors. Associations between interleukin 13 (IL-13) levels and aGVHD were by far the strongest predictor of a GVHD (P =.0002). All patients suffering severe (grade III) aGVHD following SCT had donors who produced very high pretransplantation IL-13 responses, while those developing little or no aGVHD (grades 0-I) produced no IL-13 at all. IL-13 levels were independent of all other cytokines measured as well as cytotoxic T-lymphocyte precursor (CTLp) frequencies. The cytokines IL-5, interferon gamma (IFN-gamma), and tumor necrosis factor alpha (TNF-alpha) also predicted development of aGVHD (P <.05 for all 3), appearing to be coproduced in the assay and correlating with estimated CTLp frequencies. The data challenge the notion that aGVHD is purely a Th1-type cytokine-driven response, high-lighting a novel and highly significant link between the Th2-type cytokine IL-13 and aGVHD.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14512310     DOI: 10.1182/blood-2003-01-0192

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  12 in total

1.  Cytokine levels following allogeneic hematopoietic cell transplantation: a match-pair analysis of home care versus hospital care.

Authors:  Olle Ringdén; Mats Remberger; Johan Törlén; Sigrun Finnbogadottir; Britt-Marie Svahn; Behnam Sadeghi
Journal:  Int J Hematol       Date:  2021-02-05       Impact factor: 2.490

2.  Human beta-defensin 2 induces a vigorous cytokine response in peripheral blood mononuclear cells.

Authors:  Michele Boniotto; William J Jordan; Joyce Eskdale; Alessandro Tossi; Nikolinka Antcheva; Sergio Crovella; Nancy D Connell; Grant Gallagher
Journal:  Antimicrob Agents Chemother       Date:  2006-04       Impact factor: 5.191

Review 3.  Chronic graft-versus-host disease: Pathogenesis and clinical management.

Authors:  José A Pérez-Simón; Ignacio Sánchez-Abarca; María Díez-Campelo; Dolores Caballero; Jesús San Miguel
Journal:  Drugs       Date:  2006       Impact factor: 9.546

Review 4.  Intestinal barrier loss as a critical pathogenic link between inflammatory bowel disease and graft-versus-host disease.

Authors:  S C Nalle; J R Turner
Journal:  Mucosal Immunol       Date:  2015-05-06       Impact factor: 7.313

Review 5.  Pathophysiology of acute graft-versus-host disease: recent advances.

Authors:  Yaping Sun; Isao Tawara; Tomomi Toubai; Pavan Reddy
Journal:  Transl Res       Date:  2007-07-03       Impact factor: 7.012

6.  YKL-40 in allogeneic hematopoietic cell transplantation after AML and myelodysplastic syndrome.

Authors:  B Kornblit; T Wang; S J Lee; S R Spellman; X Zhu; K Fleischhauer; C Müller; M R Verneris; K Müller; J S Johansen; L Vindelov; P Garred
Journal:  Bone Marrow Transplant       Date:  2016-07-18       Impact factor: 5.483

7.  Simultaneous analysis of cytokines and co-stimulatory molecules concentrations by ELISA technique and of probabilities of measurable concentrations of interleukins IL-2, IL-4, IL-5, IL-6, CXCL8 (IL-8), IL-10, IL-13 occurring in plasma of healthy blood donors.

Authors:  Klabusay Martin; Kohutova Viera; Coupek Petr; Nenickova Marie; Tesarova Eva
Journal:  Mediators Inflamm       Date:  2006       Impact factor: 4.711

8.  Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: A dose escalating phase I/II study.

Authors:  S L Bernhardt; M K Gjertsen; S Trachsel; M Møller; J A Eriksen; M Meo; T Buanes; G Gaudernack
Journal:  Br J Cancer       Date:  2006-10-24       Impact factor: 7.640

9.  Targeting Cytokines in GVHD Therapy.

Authors:  Sandeep Kumar; Hemn Mohammadpour; Xuefang Cao
Journal:  J Immunol Res Ther       Date:  2017-06-28

Review 10.  T Helper Cell Lineage-Defining Transcription Factors: Potent Targets for Specific GVHD Therapy?

Authors:  Julia Campe; Evelyn Ullrich
Journal:  Front Immunol       Date:  2022-01-05       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.